VKH
CASC

Virtu KCG Holdings’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Virtu KCG Holdings’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$42K Buy
11,311
+187
+2% +$742 ﹤0.01% 2632
2017
Q1 		$46K Sell
11,124
-23,239
-68% -$97.7K ﹤0.01% 2860
2016
Q4 		$148K Buy
34,363
+11,400
+50% +$73.7K ﹤0.01% 2756
2016
Q3 		$226K Buy
22,963
+15,425
+205% +$109K 0.01% 2256
2016
Q2 		$43K Sell
7,538
-7,978
-51% -$54.2K ﹤0.01% 2707
2016
Q1 		$118K Sell
15,516
-5,212
-25% -$40.1K ﹤0.01% 2286
2015
Q4 		$276K Buy
20,728
+16,546
+396% +$285K ﹤0.01% 2265
2015
Q3 		$69K Sell
4,182
-12,702
-75% -$260K ﹤0.01% 2930
2015
Q2 		$379K Buy
16,884
+14,841
+726% +$235K 0.01% 1779
2015
Q1 		$20K Sell
2,043
-4,916
-71% -$48.2K ﹤0.01% 2960
2014
Q4 		$79K Buy
6,959
+2,428
+54% +$26.4K ﹤0.01% 3313
2014
Q3 		$52K Buy
4,531
+401
+10% +$6.13K ﹤0.01% 3338
2014
Q2 		$80K Sell
4,130
-7,970
-66% -$141K ﹤0.01% 3340
2014
Q1 		$216K Sell
12,100
-664
-5% -$10.9K ﹤0.01% 2915
2013
Q4 		$134K Buy
12,764
+6,686
+110% +$74.7K ﹤0.01% 3337
2013
Q3 		$75K Buy
+6,078
New +$64K ﹤0.01% 3431

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Virtu KCG Holdings's CASC Position: Q2 2017 in Review

Virtu KCG Holdings increased its Cascadian Therapeutics, Inc. (CASC) stake by 1.7% in Q2 2017, buying an estimated $742 and bringing the position to 11,311 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Virtu KCG Holdings first reported a position in CASC in Q3 2013 and has held it in 16 quarters since. The position peaked at $379K in Q2 2015. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Virtu KCG Holdings held 11,311 shares of Cascadian Therapeutics, Inc. worth $42K as of Q2 2017.
  • Virtu KCG Holdings bought 187 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $742.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2632 holding.
  • Virtu KCG Holdings first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and has held it in 16 quarters since.
  • Virtu KCG Holdings's Cascadian Therapeutics, Inc. position peaked at $379K in Q2 2015.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.